Can I apply for free use of bosutinib/bosutinib?

Bosutinib/Bosutinib is a targeted drug for the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia (CML). Its high drug cost puts many patients under financial pressure when receiving treatment. Therefore, applying for free medication or obtaining medication assistance has become a focus for some patients.

In China, some hospitals and drug manufacturers will set up free medication or drug assistance programs to help patients with poor financial conditions. This kind of assistance is usually provided by pharmaceutical companies, charitable organizations or related medical institutions. The purpose is to ensure that patients can receive necessary treatment without delaying their illness due to financial problems. Applying for this kind of free medicine usually requires meeting certain conditions, such as the patient's financial status, the severity of the disease, and whether certain clinical criteria are met.

Specifically, when patients apply for free medicine, they usually need to provide the following materials: proof of identity, proof of family financial status, medical records issued by doctors, drug prescriptions, etc. In addition, some hospitals may also require patients to fill in an application form and undergo corresponding review procedures. During the application process, patients and their families can also consult the hospital's social worker or drug management department to learn about the specific application process and required materials.

It should be noted that although some patients have received free bosutinib through application, not all patients can successfully receive such assistance. Due to the limited number of drugs and strict application conditions, some patients may be unable to obtain free drugs. Therefore, before treatment, patients should understand the relevant policies in advance and communicate with their doctors or medical staff in order to formulate the most appropriate treatment plan.

Reference materials:https://medlineplus.gov/druginfo/meds/a613005.html